What is Cimzia?
Cimzia is a biologic medication that works to reduce the inflammation that may result from an overactive immune system. Cimzia is a monoclonal antibody that binds to and inhibits the activity of tumor necrosis factor (TNF) alpha, a protein that is involved in systemic inflammation. By stopping TNF alpha-mediated signaling, the inflammation that contributes to the development of autoimmune disorders like rheumatoid arthritis and ankylosing spondylitis is reduced and associated symptoms are improved.
Each pack of Cimzia comes with two prefilled syringes that each contain 200mg of lyophilized Cimzia that must be reconstituted. Cimzia is meant to be administered subcutaneously. The medicine must be administered by a healthcare professional. Cimzia is also available as a solution in a prefilled pen, which can be self-injected by a patient in the appropriate circumstances.
What is Cimzia used for?
Cimzia treats several autoimmune diseases, including moderate to severe rheumatoid arthritis, psoriatic arthritis, moderate to severe Crohn’s disease after the patient has failed to respond to conventional therapies, and ankylosing spondylitis. Cimzia is meant to be used alongside methotrexate to treat rheumatoid arthritis.